Genetic profiling of thymic carcinoma using targeted next-generation sequencing

Lung Cancer

Volumn 86, Issue 2, 2014, Pages 174-179

  Shitara, Masayuki ^a   Okuda, Katsuhiro ^a   Suzuki, Ayumi ^a   Tatematsu, Tsutomu ^a   Hikosaka, Yu ^a   Moriyama, Satoru ^a   Sasaki, Hidefumi ^a   Fujii, Yoshitaka ^a   Yano, Motoki ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

Author keywords

Genetic profiling; Heterogeneous; Squamous cell carcinoma; Targeted next generation sequencing; Thymic carcinoma; Tyrosine kinase gene mutation

Indexed keywords

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER TISSUE; CARCINOGENESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DDR2 GENE; EXON; FEMALE; GENE DELETION; GENE IDENTIFICATION; GENE MUTATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC PROCEDURES; HUMAN; HUMAN TISSUE; IGF1R GENE; KIT GENE; MALE; MEDIASTINUM TUMOR; MIDDLE AGED; PDGFRA GENE; RARE DISEASE; ROS1 GENE; SQUAMOUS CELL CARCINOMA; TARGETED NEXT GENERATION SEQUENCING; THYMIC SQUAMOUS CELL CARCINOMA; TUMOR GENE; BIOLOGY; CANCER STAGING; CARCINOMA; CARCINOMA, SQUAMOUS CELL; GENE EXPRESSION PROFILING; GENETICS; HIGH THROUGHPUT SEQUENCING; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; THYMUS NEOPLASMS;

AGED; CARCINOMA; CARCINOMA, SQUAMOUS CELL; COMPUTATIONAL BIOLOGY; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; THYMUS NEOPLASMS;

EID: 84908460816     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2014.08.020     Document Type: Article

References (24)

1. Weissferdt A., Wistuba I.I., Moran C.A. Molecular aspects of thymic carcinoma. Lung Cancer 2012, 78:127-132.
2. Yano M., Sasaki H., Yokoyama T., Yukiue H., Kawano O., Suzuki S., et al. Thymic carcinoma: 30 cases at a single institution. J Thorac Oncol 2008, 3:265-269.
3. Weksler B., Dhupar R., Parikh V., Parikh V., Nason K.S., Ferson R.F. Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg 2013, 95:299-303.
4. Weissferdt A., Moran C.A. Thymic carcinoma, part 1: a clinicopathologic and immunohistochemical study of 65 cases. Am J Clin Pathol 2012, 138:103-114.
5. Kondo K., Monden Y. Therapy for thymic epithelial tumors: a clinical study of 1320 patients from Japan. Ann Thorac Surg 2003, 76:878-884. discussion 884-75.
6. Suzuki E., Sasaki H., Kawano O., Endo K., Haneda H., Yukiue H., et al. Expression and mutation statuses of epidermal growth factor receptor in thymic epithelial tumors. Jpn J Clin Oncol 2006, 36:351-356.
7. Yoh K., Nishiwaki Y., Ishii G., Goto K., Kubota K., Ohmatsu H., et al. Mutational status of EGFR and KIT in thymoma and thymic carcinoma. Lung Cancer 2008, 62:316-320.
8. Girard N., Shen R., Guo T., Zakowski M.F., Hequy A., Riely G.J., et al. Comprehensive genomic analysis reveals clinically relevant molecular distinctions between thymic carcinomas and thymomas. Clin Cancer Res 2009, 15:6790-6799.
9. Weissferdt A., Lin H., Woods D., Tang X., Fujimoto J., Wistuba I.I., et al. HER family receptor and ligand status in thymic carcinoma. Lung Cancer 2012, 77:515-521.
10. Pan C.C., Chen P.C., Wang L.S., Lee J.Y., Chiang H. Expression of apoptosis-related markers and HER-2/neu in thymic epithelial tumours. Histopathology 2003, 43:165-172.
11. Strobel P., Hartmann M., Jakob A., Mikesch K., Brink I., Dirnhofer S., et al. Thymic carcinoma with overexpression of mutated KIT and the response to imatinib. New Engl J Med 2004, 350:2625-2626.
12. Sasaki H., Yano M., Fujii Y. Evaluation of Kras gene mutation and copy number in thymic carcinomas and thymomas. J Thorac Oncol 2010, 5:1715-1716.
13. Hirabayashi H., Fujii Y., Sakaguchi M., Tanaka H., Yoon H.E., Komoto Y., et al. p16INK4, pRB, p53 and cyclin D1 expression and hypermethylation of CDKN2 gene in thymoma and thymic carcinoma. J Int du Cancer 1997, 73:639-644.
14. Tateyama H., Eimoto T., Tada T., Mizuno T., Inagaki H., Hata A., et al. p53 protein expression and p53 gene mutation in thymic epithelial tumors. An immunohistochemical and DNA sequencing study. Am J Clin Pathol 1995, 104:375-381.
15. Stadler Z.K., Schrader K.A., Vijai J., Robson M.E., Offit K. Cancer genomics and inherited risk. J Clin Oncol 2014.
16. Yamakawa Y., Masaoka A., Hashimoto T., Niwa H., Mizuno T., Fujii Y., et al. A tentative tumor-node-metastasis classification of thymoma. Cancer 1991, 68:1984-1987.
17. Kumar P., Henikoff S., Ng P.C. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nat Protoc 2009, 4:1073-1081.
18. Kelly R.J., Petrini I., Rajan A., Wang Y., Giaccone G. Thymic malignancies: from clinical management to targeted therapies. J Clin Oncol 2011, 29:4820-4827.
19. Heinrich M.C., Corless C.L., Demetri G.D., Blanke C.D., von Mehren M., Joensuu H., et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003, 21:4342-4349.
20. Hagemann I.S., Govindan R., Javidan-Nejad C., Pfeifer J.D., Cottrell C.E. Stabilization of disease after targeted therapy in a thymic carcinoma with KIT mutation detected by clinical next-generation sequencing. J Thorac Oncol 2014, 9:e12-e16.
21. Hammerman P.S., Sos M.L., Ramos A.H., Xu C., Dutt A., Zhou W., et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov 2011, 1:78-89.
22. Stransky N., Egloff A.M., Tward A.D., Kostic A.D., Cibulskis K., Sivachenko A., et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011, 333:1157-1160.
23. Agrawal N., Frederick M.J., Pickering C.R., Betteqowda C., Chang K., Li R.J., et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 2011, 333:1154-1157.
24. Maitra A., Biswas N.K., Amin K., Kowtal P., Kumar S., Das S., et al. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently mutated genes and molecular subgroups. Nat Commun 2013, 4:2873.